TROMS0, Norway--(BUSINESS WIRE)--The Scandinavian-based drug development company Lytix Biopharma announced its intention to take its lead ultra-broad spectrum antimicrobial through to clinical trials. Broadly effective through rapid and selective cell lysis against even highly resistant bacterial strains such as MRSA, this novel class of small molecules exhibits an extremely low propensity for resistance development.
